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SenSory SyStemS DiSorDerS – Clinical outcomes Studies
PSS1
ComParing the effiCaCy of anti-VaSCular enDothelia growth 
faCtor DrugS for treatment of age-relateD maCular Degeneration: 
a CliniCal literature reView anD meta-analySiS
Zhao R., Su W., Carlson A.
University of Minnesota, Minneapolis, MN, USA
Objectives: Review and compare the efficacy of four anti-VEGF (vascular endothelia 
growth factor) drugs for treatment of neovascular age-related macular degenera-
tion (AMD). MethOds: PubMed and clinicaltrials.gov databases were searched to 
identify studies of four anti-VEGF drugs: ranibizumab, bevacizumab, aflibercept, and 
pegaptanib. Eight randomized controlled trials were selected. Fixed-effects model 
was used to pool the data to determine Mantel-Haenszel adjusted relative risk. The 
primary outcome was relative risk (RR) of losing 15 or more letters of visual acuity at 
one year follow-up. The secondary outcome was RR of gaining 15 or more letters of 
visual acuity at one year follow-up. Results: Ranibizumab 0.3 mg or ranibizumab 0.5 
mg significantly reduced the risk of losing 15 or more letters of visual acuity compared 
to sham (RR: 0.15 and 0.13 respectively, p< 0.05). RR of visual acuity gain of 15 letters or 
more was 5.5 for ranibizumab 0.3 mg versus sham (95% CI: 3.5-8.67). The visual acuity 
gain was also significantly higher for ranibizumab 0.5 mg than ranibizumab 0.3 mg 
(RR: 1.24, p< 0.05). There were no significant differences between bevacizumab 1.25 
mg and ranibizumab 0.5 mg in terms of visual acuity loss or gain (RR: 1.17 and 1.04 
respectively, p: 0.46 and 0.69 respectively). Aflibercept 0.5 mg have comparable efficacy 
as ranibizumab 0.5 mg. Pegaptanib reduced the risk of losing 15 letters or more versus 
sham (RR: 0.67, p< 0.05). The RR of gaining 15 or more letters for visual acuity was 3.3 
for pegaptanib versus sham (95% CI: 1.22-7.52). cOnclusiOns: All four anti-VEGF 
drugs reduced the risk of visual acuity loss in patients with AMD. Ranibizumab 0.5 
mg is associated with more visual acuity gain than ranibizumab 0.3 mg. However, 
there is no direct evidence that one treatment is better than the other. More studies 
are needed to compare the efficacy and safety between these drugs.
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PharmaCologiCal treatmentS in Pregnant women with PSoriaSiS
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Objectives: Psoriasis treatment in pregnant women requires weighing the risks 
and benefits to both mother and fetus. Little is known about how psoriasis is treated 
during pregnancy. This study sought to identify the medications most commonly 
prescribed in this situation. MethOds: The Truven 2003-2007 MarketScan™ 
Medicaid Database was used. Pregnant women with psoriasis were identified by 
inpatient and outpatient records. The investigators created an algorithm to identify 
eligible pregnant women and approximated their gestational periods using this 
claims database to identify drug use during pregnancies. The prevalence of drug 
use was determined by the proportion of prescriptions. The top 10 most popu-
lar prescriptions as well as methotrexate were identified based on the proportion 
overall and by trimester of pregnancy. Use of topical corticosteroids were revealed 
by drug potency. Results: Based on the algorithm created by the investigators, 
974 pregnant women with psoriasis were identified, and 386 (39.6%) of them filled 
psoriasis drugs and saw a physician for psoriasis before pregnancy. The most com-
mon medications prescribed most patients were topical corticosteroids (n= 122, 
31.6%). Of those patients given topical corticosteroids, the majority were low to 
mid-potency (64.8%). The second most common drug type (n= 41, 10.4%) used was 
“other” products such as topical vitamin-D analogues and pimecrolimus. This was 
followed by biologics (n= 2, 0.5%) and other systemic treatments (n= 2, 0.5%). Two 
patients received methotrexate during their pregnancy- one of which received it 
for the entire gestational period. cOnclusiOns: This study revealed the preva-
lence of psoriasis medications used in pregnant women with psoriasis, which could 
provide information in how risks and benefits of psoriasis treatment in pregnant 
women were weighed. In general, dermatologist prescribing patterns were in line 
with treatment recommendations for pregnant women. However, there were some 
treatments prescribed that were not suitable for pregnant women. Care should be 
to ensure safe treatments for pregnant women.
SenSory SyStemS DiSorDerS – Cost Studies
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Objectives: Dental caries is associated with poor quality of life and higher 
health care cost. This study aimed to assess the cost of treatment of dental car-
ies of preschool children (3 to 6 years old) and to characterize predictors of these 
costs. MethOds: 194 preschool children were selected by random sampling from 
six kindergarten in urban Beijing. Oral health examinations of these children were 
performed in Stomatological Hospital of Peking University and questionnaires were 
distributed to all tested preschool children’s parents. All information of children’s 
dietary and oral hygiene habits, demographic characters, clinical, parents’oral 
“knowledge, attitudes, and practices” and costs were collected for the analysis. 
We used generalized estimating equations to examine potential predictors of the 
costs. Results: Among 194 dental caries children (mean age = (4.4±1.1) years; 
50% female), the average cost of treatment was RMB718.6 yuan (median:¥400, 
IQR:¥150-¥1000). The multiple linear regressions showed that the treatment cost of 
children with 5 ~ 8 dental caries had 24.2% higher costs than those with 1 ~ 5 dental 
caries;(P< 0.05). The treatment cost of children with more than 8 dental caries had 
47.8% higher costs than those with 1 ~ 5 dental caries; (P< 0.05). cOnclusiOns: 
Objectives: Tobacco smoke is a strong risk factor for chronic obstructive pulmo-
nary disease (COPD), and over 300 million people are estimated to smoke in China. 
This study examined characteristics and treatment patterns of COPD-diagnosed 
patients attempting to quit smoking in urban China. MethOds: National Health 
and Wellness Survey (NHWS) 2010 and 2012 China data were analyzed. NHWS is a 
mixed-methodology, internet-based, nationwide survey of adults (18+ years) strati-
fied by gender and age to represent the demographic composition of urban China. 
Inclusion criteria comprised self-reported diagnosis with COPD and current smokers 
“trying to quit” or non-smokers “in the process of quitting.” Sociodemographics, 
health behaviors, Charlson comorbidity index (CCI) scores (indicating degree of mor-
tality risk), and smoking treatment utilization patterns were assessed. Descriptive 
statistics included percentages/frequencies for categorical variables and means/
standard deviations for continuous variables. Results: Among 1,421 respondents 
diagnosed with COPD, 35.5% (n= 505) were smokers, among which 43.8% (n= 221) 
were currently attempting to quit. Quit attempters were on average 41.1 years old 
(SD= 13.1), male (76.5%), employed (86.9%), 34.8% were overweight/obese, and they 
had been diagnosed with COPD an average 6.9 years (SD= 7.7), with 25.3% report-
ing moderate/severe COPD. Mean CCI was 2.53, 57.5% drank alcohol regularly, and 
30.3% exercised frequently. Many reported smoking as the main cause of their COPD 
(57.5%), followed by illnesses/conditions (53.8%) and pollutants/airborne irritants 
(44.3%). Current smoking was reported by 82.8%, with 14.9% smoking daily. Smoking 
cessation prescription use was reported by 12.7% (n= 28), among whom varenicline 
tartrate was used by 57.1% (n= 16) for an average 20.9 months. Prescription medi-
cations were commonly received from urban/city (50%) or county (35.7%) hospi-
tals. cOnclusiOns: Among COPD patients attempting to quit smoking in urban 
China, few utilized prescription cessation treatments. Given the significant unmet 
need among the high proportion of smokers with COPD, effective smoking cessa-
tion programs are needed.
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Objectives: Asthma is a chronic disease afflicting more than 300 million people 
throughout the world . Our aim was to examine the availability, pricing and afford-
ability of asthma medicines in Tehran. MethOds: We followed the methodological 
recommendations developed of the World Health Organization and Health Action 
International on measuring medicine prices, availability, affordability and price 
components. Data was collected from a random selection of 30 public sector facili-
ties and 90 private sector retail pharmacies in 22 districts of Tehran in September 
2012. Results: Inhaled Corticosteroids was found in over 25% of the pharmacies. 
The availability of oral corticosteroids and short acting beta agonists was poor in 
all districts of Tehran. Locally manufactured most commonly prescribed medicines 
(beta-agonist and corticosteroid sprays) were affordable as the of cost of one month 
utilization was about 0.3 of one day (equivalent to one day) earning for the unskilled 
worker for the insured (uninsured). However the availability of the asthma medi-
cines were limited and ranged from less than 5% (for the imported sprays) to about 
a third (for the locally manufactured sprays) of the outlets. cOnclusiOns: The 
poor availability of inhalers at public facilities affects those patients who depend 
on these facilities for treatment and medications. In relation with imported asthma 
medicines, results indicate access to asthma medicine has been reduced in most 
medicines, perhaps due to the international sanctions that affected the country in 
2012. Further interventions are required to improve access to asthma medicines at 
the times of financial hardship and international sanctions affecting the ability of 
the importers and producers to provide medicines.
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Objectives: Short-acting β 2-agonists - albuterol and levalbuterol - are widely pre-
scribed to prevent asthma exacerbations. However, there are significant cost dif-
ferences between the two medications. The objective of this study is, therefore, to 
examine the economic impact of levalbuterol versus albuterol on total health care 
expenditure in a high-risk, low income asthma population. MethOds: A retrospec-
tive cohort study was conducted among asthmatic patients aged 2-64 years old who 
received levalbuterol or albuterol in the South Carolina Medicaid database between 
January 2001 and December 2012. Expenditures were inflated to 2011 dollars using 
the gross domestic product deflator, and adjusted using generalized linear models 
with a gamma distribution and log-link function. Propensity score matching was 
performed to minimize the possible bias related to unbalanced groups. Results: 
A total of 9,370 asthma patients were included in the cohort (levalbuterol: 1,652; 
albuterol: 7,718). The annual spending on levalbuterol was approximately 5 times 
more than albuterol ($272.6 vs. $56.0, p< .001). After adjustment for age, sex, race, 
year of index date, length of asthma, and proportions of days covered by asthma 
control medications, levalbuterol group demonstrated lower asthma-related expen-
ditures on emergency department ($101.3 vs. $143.1, p< .001), hospital ($40.8 vs. 
$85.0, p< .001), outpatient facility ($77.6 vs. $109.1, p< .001) visits, and total health 
care ($386.3 vs. $488.1, p< .001). However, there were no statistically significant 
differences between levalbuterol and albuterol on total health care expenditures 
(levalbuterol: $4041.7 vs. albuterol: $3903.1, p= .41). This nonsignificant difference 
remained when using the propensity score matching method. cOnclusiOns: More 
than 300 million people suffer from asthma worldwide. The use of levalbuterol was 
associated with lower asthma-related costs on ED visits, hospitalizations or outpa-
tient facilities. These cost savings, however, failed to offset the high cost of acquiring 
levalbuterol, suggesting that levalbuterol did not generate greater economic impact 
than albuterol on low-income asthma population.
